Ultragenyx Pharmaceutical Inc. Stock
Ultragenyx Pharmaceutical Inc. shows a slight decrease today, losing -€0.400 (-0.990%) compared to yesterday.
We see a rather positive sentiment for Ultragenyx Pharmaceutical Inc. with 17 Buy predictions and 1 Sell predictions.
Based on the current price of 39.8 € the target price of 84 € shows a potential of 111.06% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Ultragenyx Pharmaceutical Inc. | -0.990% | -3.865% | -7.870% | 3.109% | -8.716% | -56.264% | -34.765% |
Ironwood Pharmaceuticals | 6.210% | 4.054% | 1.987% | -18.085% | -24.510% | -15.847% | - |
Sage Therapeutics Inc. | -3.520% | 1.448% | -19.076% | -68.390% | -35.200% | -80.196% | - |
Novocure Ltd | 2.120% | 16.088% | 3.044% | -77.020% | -3.958% | -91.837% | - |
Comments
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $59.00 to $61.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat